BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra has signed a ten-year enterprise imaging contract with St. Claraspital in Basel, Switzerland.

Intersect ENT, Inc. announced the results of a United Kingdom-based independent analysis measuring costs and patient outcomes of the PROPEL steroid releasing sinus implant compared to a non-drug-eluting spacer following endoscopic sinus surgery for patients with chronic sinusitis.

The ongoing corona pandemic has created great global demand for respiratory protection.

Dr. Christopher Otiko, President of ViaDerma, said “I am very pleased with the progress we are making on several fronts. Medical sales are typically not quick to close and often take time to bring to fruition.

Preceptis Medical is pleased to announce that the Hummingbird® Tympanostomy Tube System has received US Food and Drug Administration 510 clearance for use in children in the ENT surgeon’s office.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces the enrollment of the first patient in a Phase I/IIa clinical trial of BI-1206 in combination with anti-PD-1 therapy KEYTRUDA® for patients with solid tumors.

BrainStorm Cell Therapeutics Inc. announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its Verdélite Sciences subsidiary in St. Eustache, Québec, has launched its new Souvenir cannabis brand in the province. The Souvenir product line initially consists of select dried flower products from two Emerald cultivars, Grapefruit GG4 and Chemdog. The first shipments have been made to the SQDC, Québec’s cannabis distribution board, and

Inaugural Community Impact Report underscores Delta Dental’s commitment to expanding access to oral health care

Sana Biotechnology, Inc., focused on engineering cells as medicines for patients, announced the funding of all tranches of its initial financing, raising over $700 million.